SCHEMBL4524328

SCHEMBL4524328

Cc1nc(N)oc1-c1cccc(-c2ccccc2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.50
NUDT1 P36639 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.41
GAA P10253 1/20 0.41
MAOA P21397 1/20 0.41
NOTUM Q6P988 2/20 0.40
DHFR P00374 1/20 0.38
BRD4 O60885 1/20 0.38
TDO2 P48775 1/20 0.38
PSMB8 P28062 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
MAPK13 O15264 1/20 0.37
MAPK12 P53778 1/20 0.37
MAPK11 Q15759 1/20 0.37
MAPK14 Q16539 1/20 0.37
FBP1 P09467 1/20 0.37
BACE1 P56817 1/20 0.37
MECP2 P51608 1/20 0.37
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5318103 0.88 NR4A2 (0.63) NR4A2NUDT1L3MBTL1NOTUMBRD4
SCHEMBL4523610 0.82 RAB9A (0.45) NR4A2GAAMAOAMEN1KMT2A
SCHEMBL4518811 0.80 SMN1; SMN2 (0.47) L3MBTL1GAADHFRMEN1KMT2A
SCHEMBL4527722 0.77 NR4A2 (0.50) NR4A2NUDT1L3MBTL1GAAMAOA
SCHEMBL22925728 0.73 KDM4E (0.48) NR4A2NUDT1L3MBTL1MEN1KMT2A
SCHEMBL4828418 0.70 DHFR (0.50) NR4A2NUDT1L3MBTL1GAAMAOA
SCHEMBL342242 0.69 MAPK13 (0.58) NR4A2L3MBTL1GAABRD4MEN1
SCHEMBL22925906 0.68 KIF11 (0.46) NR4A2GAANOTUMNPC1
SCHEMBL330227 0.67 NR4A2 (1.00) NR4A2L3MBTL1GAANOTUMMAPK13
SCHEMBL869242 0.67 GAA (0.51) NR4A2GAAMAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090018150-A1 5-Ht2b Receptor Antagonists ASTERAND UK LIMITED (GB) 2009-01-15 US disclosed
US-20090018150-A1 5-Ht2b Receptor Antagonists ASTERAND UK LIMITED (GB) 2009-01-15 US disclosed
US-20090018150-A1 5-Ht2b Receptor Antagonists ASTERAND UK LIMITED (GB) 2009-01-15 US disclosed
EP-1648876-A1 5-HT SB 2B /SB RECEPTOR ANTAGONISTS Pharmagene Laboratories Ltd (GB) 2006-04-26 EP disclosed
WO-2005012263-A1 5-HT2B RECEPTOR ANTAGONISTS PHARMAGENE LABORATORIES LIMITED (GB) 2005-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018150-A1 5-Ht2b Receptor Antagonists HTR2B, HTR1B, HTR3B NR4A2 1040/4885NUDT1 1933/4885L3MBTL1 4705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.